Who
Cam Gallagher
Director
Company insider
Files Form 4 as: Director, Opus Genetics; President, Interim CFO, Zentalis Pharmaceuticals; Director, Sorrento Therapeutics.
In numbers
- Trades disclosed
- 183
- Buys
- 2
- Sells
- 49
- Bought
- $324K
- Sold
- $22.3M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 17 Oct 2012
- Last trade
- 8 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 8 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code M | $902K784,314 at $1.15 | filing |
| 8 Sep 2026filed 8 Sep 2026 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —784,314 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —784,314 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code M | $902K784,314 at $1.15 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 31 Dec 2025filed 31 Dec 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 29 Dec 2025filed 31 Dec 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Bought | $160K81,000 at $1.98 | filing |
| 29 Dec 2025filed 31 Dec 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Bought | $164K83,000 at $1.97 | filing |
| 25 Aug 2025filed 27 Aug 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | $1000K869,565 at $1.15 | filing |
| 30 Apr 2025filed 2 May 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —79,592 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —79,504 at $0.00 | filing |
| 24 Mar 2025filed 26 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —784,314 | filing |
| 24 Mar 2025filed 26 Mar 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —784,314 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,181 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —41,143 at $0.00 | filing |
| 31 May 2024filed 31 May 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $115K9,597 at $11.98 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $13K1,173 at $11.44 | filing |
News
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026Opus Genetics to Present at the Chardan Annual Healthcare ConferenceIRD · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Cam Gallagher; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.